2 terminated, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Nabil Adra: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Etoposide - Germ Cell Tumor, Non-seminomatous Germ Cell Tumor | Phase 2 | Recruiting | Nabil Adra | 64 | 2021-03-03 | 2026-05-08 |
| Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Carboplatin, Gemcitabine, Atezolizumab - Urothelial Carcinoma | Phase 2 | Terminated | Nabil Adra | 6 | 2018-12-19 | 2023-09-13 |
| Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Brentuximab Vedotin - Germ Cell Tumors, Testis Cancer | Phase 2 | Terminated | Nabil Adra | 18 | 2016-03-09 | 2019-12-10 |
| Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Pembrolizumab, Vorinostat - Renal Cell Carcinoma, Urinary Bladder Neoplasms | Phase 1 | Completed | Nabil Adra | 52 | 2016-02-23 | 2024-11-18 |
Neoplasms, Germ Cell and Embryonal (2) · Nonseminomatous germ cell tumor (2) · Carcinoma, Embryonal (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Testicular Neoplasms (1) · Urinary Bladder Neoplasms (1)
Brentuximab Vedotin (1) · Carboplatin (1) · Docetaxel (1) · Etoposide (1) · Gemcitabine (1) · Vorinostat (1) · atezolizumab (1) · pembrolizumab (1)
United States (4)
Costantine Albany, MD (1) · Roberto Pili, MD (1)